Analysis updated Nov 8, 2026 — scores and signals refreshed daily.
Cytokinetics Incorporated Common Stock (CYTK) stock research. Updated Nov 8, 2026. Q-Score 37/100 — Sell. Fair value, forecast, technicals, and insider activity.
Current Q-Score verdict: Sell (37.0) (grade D). 43 signals analyzed (38 differentiated alt-data).
StoQuant's analysis of Cytokinetics Incorporated Common Stock (CYTK) is refreshed every trading day. The Q-Score combines discounted cash flow valuation, earnings quality, competitive moat, analyst consensus, ML return forecasts, technical momentum and market sentiment into a single 0–100 composite. Insider transactions from SEC Form 4 filings, the Graham intrinsic value estimate and signal coverage are recomputed as new data arrives, so this page always reflects the latest available information.
CYTK stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-08-10 | $77.89 | $75.67 | $77.49 |
| 2026-08-18 | $76.81 | $74.76 | $76.10 |
| 2026-08-26 | $79.88 | $76.70 | $79.20 |
| 2026-09-03 | $74.22 | $71.41 | $73.95 |
| 2026-09-14 | $74.65 | $72.34 | $72.45 |
| 2026-09-22 | $69.56 | $67.48 | $67.59 |
| 2026-09-30 | $66.92 | $65.25 | $65.91 |
| 2026-10-08 | $62.79 | $59.79 | $62.01 |
| 2026-10-16 | $63.90 | $61.69 | $61.95 |
| 2026-10-26 | $61.89 | $60.48 | $60.73 |
| 2026-11-03 | $64.37 | $62.05 | $62.31 |
How Cytokinetics Incorporated Common Stock stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| AZN | AstraZeneca PLC | $290.7B | — |
| NVS | Novartis AG | $287.1B | — |
| NVO | Novo Nordisk A/S | $200.3B | — |
| SNY | Sanofi | $107.6B | — |
| GSK | GSK plc | $102.1B | — |
View all Health Care stocks by valuation and signals →
Cytokinetics Incorporated Common Stock (CYTK) scores Sell (37.0), and the composite conceals a 81-point disagreement between its dimensions. It is strongest on competitive moat at 99 and valuation at 77, and weakest on earnings quality at 24 and technicals at 18. A stock can carry competitive moat that high while technicals sits at 18; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 99 |
| valuation | 77 |
| analyst consensus | 65 |
| earnings quality | 24 |
| technicals | 18 |
StoQuant analyzes 43 signals (38 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Cytokinetics Incorporated Common Stock (CYTK): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
Browse daily research picks • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and IC-weighted signals (live edge on /proof). We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/CYTK"><img src="https://stoquant.com/badge/CYTK.svg" alt="Cytokinetics Incorporated Common Stock (CYTK) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Free StoQuant digest by email. No account needed. See today's research picks.